{
  "id": "5d2360284c435283",
  "title": "Johnson & Johnson receives European Commission approval of IMAAVY\u00ae\u25bc (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)",
  "description": "Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demons\u2026",
  "content": "BEERSE, BELGIUM (01 December, 2025) Johnson &amp; Johnson today announced that the European Commission has approved a Marketing Authorisation for IMAAVY\u00ae(nipocalimab), a fully human FcRn-blocking mon\u2026 [+22390 chars]",
  "source": "Jnj.com",
  "source_url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-european-commission-approval-of-imaavy-nipocalimab-a-new-fcrn-blocker-offering-sustained-disease-control-in-a-broad-population-of-people-living-with-generalised-myasthenia-gravis-gmg",
  "published_at": "2025-12-02T19:29:35Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "ai_machine_intelligence",
  "subcategory": null,
  "keywords": [
    "ai",
    "ipo",
    "search:regulatory agency action"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "Jnj.com"
    },
    "author": null,
    "title": "Johnson & Johnson receives European Commission approval of IMAAVY\u00ae\u25bc (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)",
    "description": "Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demons\u2026",
    "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-european-commission-approval-of-imaavy-nipocalimab-a-new-fcrn-blocker-offering-sustained-disease-control-in-a-broad-population-of-people-living-with-generalised-myasthenia-gravis-gmg",
    "urlToImage": null,
    "publishedAt": "2025-12-02T19:29:35Z",
    "content": "BEERSE, BELGIUM (01 December, 2025) Johnson &amp; Johnson today announced that the European Commission has approved a Marketing Authorisation for IMAAVY\u00ae(nipocalimab), a fully human FcRn-blocking mon\u2026 [+22390 chars]"
  }
}